- All sections
- A - Human necessities
- A61K - Preparations for medical, dental or toiletry purposes
- A61K 31/41 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which is nitrogen, e.g. tetrazole
Patent holdings for IPC class A61K 31/41
Total number of patents in this class: 2846
10-year publication summary
|
167
|
203
|
181
|
170
|
164
|
163
|
157
|
131
|
116
|
0
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Novartis AG | 11297 |
84 |
| SK Biopharmaceuticals Co., Ltd. | 257 |
72 |
| Merck Sharp & Dohme Corp. | 2218 |
44 |
| Bristol-myers Squibb Company | 4886 |
38 |
| Allergan, Inc. | 2445 |
35 |
| Merck Sharp & Dohme LLC | 3742 |
35 |
| Boehringer Ingelheim International GmbH | 4762 |
26 |
| The Regents of the University of California | 19479 |
25 |
| F. Hoffmann-La Roche AG | 7942 |
23 |
| AstraZeneca AB | 2961 |
17 |
| Bayer Pharma AG | 1085 |
15 |
| Boryung Pharmaceutical Co., Ltd. | 66 |
15 |
| Shenzhen Salubris Pharmaceuticals Co., Ltd | 82 |
15 |
| Scandion Oncology A/S | 26 |
15 |
| Genentech, Inc. | 3864 |
14 |
| Janssen Pharmaceutica N.V. | 3625 |
14 |
| Centre National de La Recherche Scientifique | 10052 |
14 |
| The Johns Hopkins University | 5519 |
14 |
| Rigel Pharmaceuticals, Inc. | 586 |
14 |
| Theravance Biopharma R&D IP, LLC | 517 |
14 |
| Other owners | 2303 |